Semaglutide
Incretin receptor agonist studied in vitro.
Specification
- Catalogue ID: SP138
- Listed purity specification: 99.8%
- Formulation: Lyophilized
- Quantity: 10mg / Vial
- Price: £77.00
GLP-1 receptor · incretin pharmacology research
Semaglutide is a synthetic 31-amino-acid GLP-1 receptor (GLP-1R) agonist featuring a fatty-acid side chain (C18 diacid via a linker) conjugated to a modified GLP-1 backbone. The fatty-acid modification enables albumin binding, which is responsible for its extended plasma half-life compared to native GLP-1. Vivera supplies it strictly as a research reagent.
In GLP-1R binding and functional assays, semaglutide is a full agonist that activates Gαs-coupled adenylyl cyclase signalling and β-arrestin recruitment. It is used as a high-potency reference compound in comparative GLP-1R pharmacology studies including receptor-binding kinetics, internalisation assays, and biased-agonism investigations.
No physiological or therapeutic properties are claimed; supplied strictly as a research reagent for in-vitro laboratory use only. Not for human or clinical use.
Compound identity
- CAS number: 910463-68-2
- Molecular formula: C₁₈₇H₂₉₁N₄₅O₅₉
- Molecular weight: 4113.58 Da
- Solubility: Soluble in water; stable in aqueous solution
- Reconstitution: Reconstitute lyophilised powder in bacteriostatic water; consult vial label for specific volume
For in-vitro laboratory research use only. Not for human or veterinary use, consumption, or therapeutic application. No medical claims are made.